Aktienanalyse zu Anbio Biotechnology (NNNN)NNNNAnbio Biotechnology

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). It operates in the Healthcare sector.

Anbio Biotechnology (NNNN) is not a good buy right now due to its significant price decline and poor technical indicators. The current price is $3.13, which has dropped 89.38% year-to-date and 40.38% over the past 20 days. Additionally, the RSI is extremely low at 6.77, indicating oversold conditions, but this could suggest further downside risk rather than an immediate buying opportunity. The forward P/E ratio is currently at 0, which may indicate uncertainty about future earnings, and the gross margin is high at 92.32% for Q2 2025, but this is overshadowed by the overall negative performance and market sentiment.